The European Medicines Agency recommended that marketing authorisation for Merck KGaA's psoriasis drug Raptiva be suspended, saying the benefits of the drug "no longer outweigh its risks, because of safety concerns."
Additionally, the FDA issued a public health advisory stating that it received three confirmed reports of progressive multifocal leukoencephalopathy in patients taking Raptiva.
1 comment:
Hot off the rumour mill - have you heard that Merck maybe considering acquiring BMS?
Post a Comment